Hamrose Gold Capsule is a combination pharmaceutical formulation containing Aspirin (75 mg), Rosuvastatin (10 mg), and Clopidogrel (75 mg), designed for the management and prevention of cardiovascular diseases. Aspirin, an antiplatelet agent, irreversibly inhibits cyclooxygenase, thereby reducing thromboxane A2 synthesis and preventing platelet aggregation. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), contributing to the stabilization of atherosclerotic plaques. Clopidogrel, another antiplatelet agent, selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor, thereby preventing platelet activation and aggregation. The combined action of these agents provides synergistic benefits in reducing the risk of myocardial infarction, stroke, and other thrombotic cardiovascular events in patients with established atherosclerotic disease or those at high risk. Hamrose Gold Capsule should be administered under medical supervision, with careful monitoring for potential adverse effects such as bleeding, hepatic dysfunction, or hypersensitivity reactions. It is contraindicated in patients with active bleeding, severe liver disease, or known hypersensitivity to any component. This combination therapy is intended as part of a comprehensive cardiovascular risk reduction strategy including lifestyle modification.